 Regencell Bioscience Holdings Limited NASDAQ: RGC announced the results from the EARTH efficacy trial of its COVID-19 candidate. RGC-COV19 Regencell Bioscience RGCA-CV01 liquid formulation is an oral TCM candidate. 